Improvement of time in therapeutic range with warfarin by pharmaceutical intervention

被引:5
|
作者
Viquez-Jaikel, Alvaro [1 ,2 ]
Hall-Ramirez, Victoria [3 ]
Ramos-Esquivel, Allan [4 ]
机构
[1] Hosp San Juan Dios, Unidad Atenc Farmaceut, Caja Costarricense Seguro Social, San Jose, Costa Rica
[2] Univ Autonoma Ciencias Med, Farm Hospitalaria, San Jose, Costa Rica
[3] Univ Costa Rica, Ctr Informac Medicamentos, Escuela Farm, San Jose, Costa Rica
[4] Univ Costa Rica, Dept Farmacol, Escuela Med, POB 2060, San Jose, Costa Rica
关键词
Anticoagulants; Costa Rica; Drug monitoring; International normalized ratio; Pharmaceutical intervention; Warfarin; NORMALIZED RATIO CONTROL; ATRIAL-FIBRILLATION; ORAL ANTICOAGULANT; QUALITY;
D O I
10.1007/s11096-016-0403-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background Anticoagulation therapy with warfarin is highly effective for prevention and treatment of thromboembolic disorders. Nevertheless, its management is challenging especially in developing countries, where the medical access is difficult and patient education is poor. Objective To determine the effect of pharmaceutical intervention (PI) on the time in therapeutic range (TTR) of a group of anticoagulated patients from our referral center. Method A group of consecutive outpatients previously treated by usual medical care underwent PI. The intervention consisted in the identification and avoidance of food and drug interactions, the confection of medication schedule charts and education to patients regarding side effects and drug monitoring. Mean TTR before and after PI was compared through the Wilcoxon test for repeated measures. Regression analyses were performed to assess the relationship between a TTR level under 65% and potential explanatory variables. Results Mean TTR before PI was 37.4 +/- 23.5% and after PI it raised to 67.0 +/- 24.9%. Mean change in TTR was +29.5% (95% CI 14.5-44.6; p < 0.001). Before PI only 4 patients had TTR values above 65%, in contrast to 18 patients after PI. Conclusion Our findings support the efficacy of PI to improve TTR values in patients treated with warfarin.
引用
收藏
页码:41 / 44
页数:4
相关论文
共 50 条
  • [21] Proton pump inhibitors co-prescribed with warfarin reduce warfarin control as measured by time in therapeutic range
    Bertram, Victoria
    Yeo, Kelly
    Anoopkumar-Dukie, Shailendra
    Bernaitis, Nijole
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2019, 73 (11)
  • [22] Patients' time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic
    Lee, Siew Ling
    Ong, Thien Jian
    Mazlan-Kepli, Wardati
    Mageswaran, Annuysia
    Tan, Kai Hsin
    Abd-Malek, Abdul-Muizz
    Cronshaw, Robert
    WORLD JOURNAL OF CARDIOLOGY, 2021, 13 (09): : 483 - 492
  • [23] Impact of Aspirin on Warfarin Control as Measured by Time in Therapeutic Range
    Boyce, Michelle L.
    Zayac, Alexa
    Davis, Arie
    Badrick, Tony
    Anoopkumar-Dukie, Shailendra
    Bernaitis, Nijole
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 123 (04) : 504 - 508
  • [24] Time to Stable Therapeutic Range on Initiation of Warfarin as an Indicator of Control
    Puttasung, Narong
    Davey, Andrew K.
    Badrick, Tony
    Anoopkumar-Dukie, Shailendra
    Bernaitis, Nijole
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2021, 30 (04)
  • [25] Time-in-therapeutic range falls as the target international normalized ratio range increases in patients on warfarin
    Malik, Imran
    Priest, Paul
    Jennings, Ian
    Gomez, Keith
    BLOOD COAGULATION & FIBRINOLYSIS, 2025, 36 (03) : 78 - 81
  • [26] Direct Oral Anticoagulants Versus Warfarin for Atrial Fibrillation in Relation to Time in Therapeutic Range: An Analysis of US Food and Drug Administration Regulatory Data
    Boesen, Kim
    Saiz, Luis Carlos
    Gotzsche, Peter C.
    Erviti, Juan
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2025, 18 (03):
  • [27] Time-in-therapeutic-range defined warfarin and direct oral anticoagulants in atrial fibrillation: a Nationwide Cohort Study
    Lehto, Mika
    Luojus, Alex
    Halminen, Olli
    Haukka, Jari
    Putaala, Jukka
    Linna, Miika
    Mustonen, Pirjo
    Kinnunen, Janne
    Lehtonen, Ossi
    Teppo, Konsta
    Tiili, Paula
    Kouki, Elis
    Itainen-Stromberg, Saga
    Niemi, Mikko
    Aro, Aapo L.
    Hartikainen, Juha
    Airaksinen, K. E. Juhani
    ANNALS OF MEDICINE, 2024, 56 (01)
  • [28] Time in the Therapeutic Range During Warfarin Therapy in Japanese Patients With Non-Valvular Atrial Fibrillation - A Multicenter Study of Its Status and Influential Factors -
    Okumura, Ken
    Komatsu, Takashi
    Yamashita, Takeshi
    Okuyama, Yuji
    Harada, Masahiko
    Konta, Yoshiyuki
    Hatayama, Toru
    Horiuchi, Daisuke
    Tsushima, Eiki
    CIRCULATION JOURNAL, 2011, 75 (09) : 2087 - 2094
  • [29] Warfarin time in therapeutic range and its impact on healthcare resource utilization and costs among patients with nonvalvular atrial fibrillation
    Deitelzweig, Steve
    Evans, Michael
    Hillson, Eric
    Trocio, Jeffrey
    Bruno, Amanda
    Tan, Wilson
    Lingohr-Smith, Melissa
    Singh, Prianka
    Lin, Jay
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (01) : 87 - 94
  • [30] The Association of Health Literacy With Time in Therapeutic Range for Patients on Warfarin Therapy
    Oramasionwu, Christine U.
    Bailey, Stacy Cooper
    Duffey, Kristin E.
    Shilliday, Betsy Bryant
    Brown, Lori C.
    Denslow, Sheri A.
    Michalets, Elizabeth Landrum
    JOURNAL OF HEALTH COMMUNICATION, 2014, 19 : 19 - 28